Study guide
14.3 Blood Administration & Patient Blood Management
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
14.3 Blood Administration & Patient Blood Management
Key Takeaways Explain This Topic AI
Independent, positive bedside patient identification against the unit tag and compatibility label immediately before infusion is the last and most effective safeguard against a fatal ABO-incompatible transfusion.
Only 0.9% normal saline may be co-administered through the same line as a blood component; lactated Ringer's (calcium can overwhelm citrate anticoagulant and trigger clotting) and dextrose-containing solutions (can cause hemolysis) are excluded.
A standard in-line filter (170-260 micron) is required for all cellular components and plasma; RBC units should generally be completed within about 4 hours to limit bacterial proliferation and product degradation at room temperature.
Patient blood management rests on three pillars: optimize hematopoiesis/red cell mass, minimize bleeding and blood loss, and harness/optimize the patient's physiologic tolerance of anemia through evidence-based restrictive strategies.
Single-unit RBC transfusion with clinical reassessment before ordering a second unit, supported by blood utilization review and electronic clinical decision support, is a core PBM practice that reduces unnecessary transfusion exposure.
Last updated: July 2026
Bedside identification: the last safety checkpoint
Most fatal ABO-incompatible transfusions trace back not to a laboratory testing error but to a bedside identification failure — the wrong unit given to the wrong patient after correct laboratory work was already done. The final safeguard is independent, positive identification : at the bedside, immediately before starting the infusion, two qualified staff members (or one staff member plus a validated electronic/barcode system, per institutional policy) verify that the patient's two unique identifiers match the unit tag, the compatibility label, and the transfusion record. This check happens at the bedside, not at the nursing station, and happens for every unit, not just the first.
Infusion practice by component
Infusion timing and rate are component-specific and are frequently tested.
Component Typical infusion window Rationale
Red blood cells Roughly 1.5-4 hours per unit; generally not to exceed about 4 hours Limits bacterial proliferation and hemolysis risk once the unit is out of controlled cold storage
Platelets Roughly 30-60 minutes, as tolerated Small volume; room-temperature storage carries higher bacterial contamination risk, favoring prompt infusion
Plasma / cryoprecipitate Infused promptly after thaw (per institutional policy and product labeling) Coagulation factor activity declines over time after thawing
Granulocytes As soon as possible after receipt; never refrigerated Short viable shelf life; leukoreduction filters must never be used because they would remove the very cells being transfused
Most transfusions begin at a slow rate for the first 10-15 minutes with the patient under direct observation, since this is the window in which most acute reactions (hemolytic, febrile, allergic) become apparent; the rate is then increased if the patient tolerates it, subject to volume and cardiac/renal tolerance limits (splitting a unit or infusing more slowly for volume-sensitive patients such as neonates, the elderly, or those with heart failure).
Compatible fluids and filtration
Blood components may be co-administered through the same line with 0.9% normal saline only . Lactated Ringer's solution contains calcium, which can overwhelm the citrate anticoagulant in the unit and trigger clot formation in the line; dextrose-containing and other hypotonic solutions can cause red cell swelling and hemolysis. Medications are never added directly to a blood component bag or line.
A standard in-line blood administration filter (170-260 micron) is required for all cellular components and plasma to remove clots and cellular debris; this is distinct from a leukoreduction filter , used when a product is not already pre-storage leukoreduced and leukoreduction is clinically indicated. Older microaggregate filters (20-40 micron) were historically used in large-volume/massive transfusion to remove platelet-leukocyte aggregates that accumulate in stored blood, though widespread pre-storage leukoreduction has reduced their routine use.
Monitoring typically includes baseline vital signs immediately before starting, a check at approximately 15 minutes (the highest-yield window for early reaction detection), and vitals at completion, with continued clinical observation throughout per institutional policy.
Patient blood management: the three-pillar framework
Patient blood management (PBM) is the specialist-level frame that ties indications, component therapy, and administration together into a coordinated strategy for reducing unnecessary transfusion exposure while protecting outcomes. It rests on three pillars.
Pillar Focus Example interventions
1. Optimize hematopoiesis / red cell mass Treat the anemia itself before it requires transfusion Detect and treat iron, B12, or folate deficiency preoperatively; consider erythropoiesis-stimulating agents when appropriate; minimize iatrogenic blood loss from frequent diagnostic phlebotomy (small-volume tubes, batched draws)
2. Minimize bleeding and blood loss Reduce the demand for transfusion at its source Meticulous surgical hemostasis; antifibrinolytics such as tranexamic acid; intraoperative cell salvage; proactive correction of coagulopathy
3. Harness and optimize physiologic tolerance of anemia Transfuse only when the evidence supports it Apply restrictive, evidence-based transfusion thresholds; use single-unit RBC orders with clinical reassessment before a second unit; avoid reflexive multi-unit ordering
The third pillar is where indications (14.1) and component dosing (14.2) become institutional practice: rather than a default two-unit order, PBM favors transfusing one unit, then reassessing the patient's clinical status and hemoglobin response before deciding whether a second unit is actually needed.
Blood utilization review
PBM is implemented and sustained through blood utilization review — transfusion committee oversight, prospective or retrospective audit of orders against indication criteria, peer review of outlier ordering patterns, and electronic clinical decision support (best-practice alerts that prompt documentation of an indication before an order is released). Specialists in blood banking are frequently the ones who design, run, and report on these review programs, making this content area as much about institutional practice as it is about the bedside encounter.
Consent, documentation, and hemovigilance
Administration is also a documentation event, not just a clinical one. Informed consent for transfusion — covering the indication, alternatives, and risks — is generally obtained before non-emergent transfusion and documented in the record; in a true emergency, transfusion may proceed under emergency-release policy with documentation completed as soon as feasible. Required administration records typically include the unique donation/unit identification number, ABO/Rh of the unit, start and stop times, the identities of the staff performing bedside verification, vital signs at baseline/15 minutes/completion, and total volume infused. This record is what makes a later transfusion reaction investigation possible: without an accurate unit number and timeline, clerical-error and hemolysis workups cannot proceed efficiently.
These records also feed hemovigilance — the systematic surveillance of adverse transfusion events and near-misses at the institutional and national level. A specialist's PBM role extends beyond any single bedside encounter: aggregated administration and reaction data drive the same blood utilization review and clinical decision support tools that make pillar three (evidence-based, restrictive transfusion) an enforceable institutional practice rather than an individual preference.